Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)

Volume 16, 10 Issues, 2017

Download PDF Flyer

CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.188
5 - Year: 2.599

Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes

CNS & Neurological Disorders - Drug Targets, 13(3): 543-552.

Author(s): Hamidreza Mahboobi, Javad Golmirzaei, Siew H. Gan, Mehrdad Jalalian and Mohammad A Kamal.

Affiliation: Hamidreza Mahboobi, Hormozgan University of Medical Sciences (HUMS), Bandar Abbas, Hormozgan, Iran.


The prevalence of Alzheimer’s disease (AD) is higher among type 2 diabetes mellitus (T2DM) patients. In T2DM patients, the progression of AD is more rapid. Furthermore, several pathophysiological pathways are common to AD and T2DM. Humanin is a recently introduced, mitochondrial-derived peptide with neuroprotective effects. Humanin can alter the mechanisms involved in AD and T2DM pathogenesis. Insulin resistance as well as oxidative stress has been shown to be associated with increased amyloid deposition in brain neurons and islet beta cells. Moreover, advanced glycation end products and lipid metabolism disorders are common pathways of oxidative stress and low-grade systemic inflammation in AD and T2DM. These common pathways may explain AD and T2DM pathogenesis and suggest common treatments for both diseases. Treatments for T2DM and AD attempt to slow cognitive decline, and recent investigations have focused on agents that may alter pathways common to AD and T2DM pathogenesis. Non-steroidal antiinflammatory drugs, such as interleukin-1 antagonists and statins, are possible drug candidates for both AD and T2DM.


Alzheimer's disease, Amyloid beta, Apo-lipoprotein E, diabetes, inflammation, oxidative stress.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Issue Number: 3
First Page: 543
Last Page: 552
Page Count: 10
DOI: 10.2174/1871527312666131223110147
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science